F-group (family)
3016.1.1.6 DegT_DnrJ_EryC1
Ligands and drugs
388
Member domains
168
with ligand contacts (≤ 4 Å)
43.3% of members
148
with DrugDomain annotations
38.1% of members
76
with a DrugBank compound
19.6% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 3016.1.1.6 belongs to X-group 3016 C-terminal domain in some PLP-dependent transferases, which binds 8.0 ligand superclasses per 20 proteins, broader than 55% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00114 | PLP | Pyridoxal phosphate | 29 |
| DB02142 | PMP | Pyridoxamine-5'-Phosphate | 15 |
| DB08845 | AKG | Oxogluric acid | 8 |
| DB03345 | BME | Mercaptoethanol | 4 |
| DB03553 | GUA | Glutaric Acid | 4 |
| DB03103 | TYD | Thymidine-5'- Diphosphate | 3 |
| DB03397 | UD1 | Uridine-Diphosphate-N-Acetylglucosamine | 2 |
| DB04762 | PDG | N-PYRIDOXYL-D-GLUTAMIC ACID-5'-MONOPHOSPHATE | 2 |
| DB02038 | DCS | D-[3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-ylmethyl]-N,O-cycloserylamide | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| PLP | PYRIDOXAL-5'-PHOSPHATE | 23 |
| CL | CHLORIDE ION | 19 |
| PMP | 4'-DEOXY-4'-AMINOPYRIDOXAL-5'-PHOSPHATE | 16 |
| NAmetal | SODIUM ION | 11 |
| TQP | (2R,3R,4S,5S,6R)-3,5-dihydroxy-4-{[(1E)-{3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methylidene]amino}-6-methyltetrahydro-2H-pyran-2-yl [(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl dihydrogen diphosphate | 11 |
| PLR | (5-HYDROXY-4,6-DIMETHYLPYRIDIN-3-YL)METHYL DIHYDROGEN PHOSPHATE | 8 |
| T5K | [[(2R,3S,5R)-5-[5-methyl-2,4-bis(oxidanylidene)pyrimidin-1-yl]-3-oxidanyl-oxolan-2-yl]methoxy-oxidanyl-phosphoryl] [(2R,3R,4S,5R,6R)-6-methyl-5-[(E)-[2-methyl-3-oxidanyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]-3,4-bis(oxidanyl)oxan-2-yl] hydrogen phosphate | 8 |
| A1ADI | 2,2'-(1,4-diazepane-1,4-diyl)di(ethane-1-sulfonic acid) | 6 |
| G4M | [(2R,3S,4R,5R)-5-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl (2R,3S,4S,5S,6R)-3,4-dihydroxy-5-[({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)amino]-6-methyltetrahydro-2H-pyran-2-yl dihydrogen diphosphate | 6 |
| O1G | 3-deoxy-3-[(E)-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methylidene)amino]-6-O-phosphono-alpha-D-glucopyranose | 6 |
| PGU | N-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methyl)-L-glutamic acid | 6 |
| 7SG | (2R,3R,4S,5R,6R)-3,5-dihydroxy-4-[(E)-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methylidene)amino]-6-methyltetrahydro-2H-pyran-2-yl [(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl]methyl dihydrogen diphosphate (non-preferred name) | 4 |
| A1APE | (2R,3R,4R,5R)-3,4-diacetamido-5-({3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methoxy)oxan-2-yl [(2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen diphosphate (non-preferred name) | 4 |
| AKG | 2-OXOGLUTARIC ACID | 4 |
| BEN | BENZAMIDINE | 4 |
| BME | BETA-MERCAPTOETHANOL | 4 |
| GPD | (2R,3S,5S,6R)-5-amino-3-hydroxy-6-methyl-oxan-2-yl | 4 |
| MGmetal | MAGNESIUM ION | 4 |
| PDG | N-({3-HYDROXY-2-METHYL-5-[(PHOSPHONOOXY)METHYL]PYRIDIN-4-YL}METHYL)-D-GLUTAMIC ACID | 4 |
| 4RA | [(2R,3R,4R,5S,6R)-3-acetamido-6-methyl-5-[(E)-[2-methyl-3-oxidanyl-5-(phosphonooxymethyl)pyridin-4-yl]methylideneamino]-4-oxidanyl-oxan-2-yl] [[(2R,3S,4R,5R)-5-[2,4-bis(oxidanylidene)pyrimidin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl] hydrogen phosphate | 3 |